Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.

Stealth BioTherapeutics Corp

A clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction.

Stealth BioTherapeutics

Careers at Stealth BioTherapeutics

Our Mission
Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. Our team works with patients and advocacy organizations to better understand their journey and raise awareness of the unmet need our programs seek to address.

We collaborate with top-tier academic and medical institutions, scientific thought leaders, and clinical key opinion leaders in developing the first generation of targeted therapies focusing on mitochondrial dysfunction as it presents in these rare genetic diseases and common diseases of aging. With these collaborative efforts, we continue to advance our platform of late-stage clinical programs and novel pipeline candidates.

Please be aware of the potential for scams claiming to represent Stealth BioTherapeutics in recruitment activities. Stealth exclusively uses @stealthbt.com e-mail addresses for recruitment purposes and does not conduct interviews via social media or other third-party sites. Please report any suspicious recruiting activity to us at careers@stealthbt.com and to the Internet Crime Complaint Center.

Sagamore Investments

Ocean Equity Partners

Pivotal bioVenture Partners

Atlantis Investment Management

BVCF

CMBC Capital Holdings

Kingdon Capital

Horizon Technology Finance

Morningside Venture Investments

Last month, we had the privilege of discussing varied pathways for patient-inspired drug development at #BIO2024. Our CEO, Reenie McCarthy, shared about our long-standing and ongoing focus on patient-directed drug development and spoke alongside I. Sika D. of Travere Therapeutics, Danae'​ Bartke of HCU Network America, Jessica Tome Garcia, Ph.D. of The Michael J. Fox Foundation for Parkinson's Research, and Stacey Frisk of The Rare Disease Company Coalition. 
 
In the eight years since the passage of the 21st Century Cures Act, patient involvement in drug development has exploded. Millions of families affected by serious conditions, particularly in #RareDisease, now have time-tested paths to follow in their pursuit of a life-changing treatment. But patient-focused drug development meetings (PFDDs) are only part of the story. In fact, different paths in drug development have emerged as varied as the challenges that patients themselves face every day. This session explored different roads taken by stakeholders to drive patient input into drug development, inspiring hope for those interested in progress toward novel therapies. #not2rare2care

We had a wonderful time connecting with others in the #MitochondrialDisease community at the United Mitochondrial Disease Foundation #MitoMed conference last week! Our CEO, Reenie McCarthy, presented an update on our clinical programs, emphasizing key learnings, the importance of perseverance, and the value of first approvals that can inform further research and advancements. We’re already looking forward to next year’s conference!

Thank you to the United Mitochondrial Disease Foundation for hosting a wonderful #MitoMed 2024 conference in Cleveland, OH! Thank you to everyone who stopped by our booth to learn more about our work in #mitochondrialdisease. It was a pleasure connecting with patients, families, advocates, researchers, clinicians, and members of the community. Until next year!

Join us at tomorrow’s virtual #MitochondrialDisease Caucus Congressional briefing, “Transforming Patient Outcomes in Mitochondrial Disease: Raising Awareness, Enabling Innovation, Driving Change.” Our CEO Reenie McCarthy will join Emily Milligan of the Barth Syndrome Foundation, Kira Mann of MitoAction, Dr. Hilary Vernon of the The Johns Hopkins University School of Medicine, and Andrew Dearth of the United Mitochondrial Disease Foundation to discuss the need for continued innovation in #MitochondrialMedicine across the patient journey – from diagnosis to drug development – and opportunities to chart a path forward. 
Register here: https://lnkd.in/ewkCbRZ3

#ICYMI: You can tune into the live replay of the recent EveryLife Foundation for Rare Diseases scientific workshop focused on the challenges and opportunities in developing much-needed therapies for ultra-rare diseases. Our CEO, Reenie McCarthy starts speaking at 1:48:40. #not2rare2care https://lnkd.in/dxJF89b

#MitoMed2024 is right around the corner and the Stealth team is excited to be in Cleveland sharing more about our work from our program in primary mitochondrial myopathy and our expanded access program. You can find all the conference details at https://umdfconference.org

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21
account payables	2.91M -	7.45M 156.24%	11.02M 47.86%	9.52M 13.63%	3.53M 62.96%	3.47M 1.67%
accumulated other comprehensive income loss	-720.81K -	-1.03M 42.73%	-1.34M 30.04%	-1.62M 21.24%	-462K 71.52%
cash and cash equivalents	9.71M -	4.12M 57.58%	10.86M 163.55%	50.77M 367.69%	32.79M 35.42%	47.13M 43.76%
cash and short term investments	9.71M -	4.12M 57.58%	10.86M 163.55%	50.77M 367.69%	32.79M 35.42%	47.13M 43.76%
common stock	20.54K -	20.54K 0.02%	20.55K 0.02%	131K 537.59%	191K 45.80%	214K 12.04%
deferred revenue					-9M -
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt		61.96M -	113.57M 83.31%	1.53M 98.66%		13.66M -
long term investments
net debt	-9.71M -	59.93M 717.24%	111.18M 85.52%	-34.53M 131.05%	-23.79M 31.10%	-33.48M 40.74%
net receivables
other assets
other current assets	1.73M -	1.80M 4.21%	2.44M 35.36%	1.63M 33.15%	2.25M 38.22%	2.47M 9.50%
other current liabilities	8.87M -	17.14M 93.31%	21.12M 23.24%	9.71M 54.01%	17.52M 80.39%	7.36M 57.99%
other liabilities
other non current assets	884.60K -	438.98K 50.37%	1.73M 294.28%		702K -	527K 24.93%
other non current liabilities	211.38M -	211.89M 0.24%	248.04M 17.06%		25.17M -	71.04M 182.22%
othertotal stockholders equity	37.52M -	39.28M 4.70%	40.88M 4.08%	516.75M 1,164.08%	545.35M 5.53%	562.47M 3.14%
preferred stock
property plant equipment net	999.53K -	795.94K 20.37%	498.55K 37.36%	345K 30.80%	106K 69.28%	97K 8.49%
retained earnings	-246.65M -	-329.56M 33.61%	-426.27M 29.35%	-498.00M 16.83%	-555.45M 11.54%	-607.98M 9.46%
short term debt			8.46M -	14.72M 73.85%	9M 38.84%
short term investments
tax assets
tax payables
total assets	13.32M -	7.15M 46.29%	15.52M 116.95%	52.74M 239.78%	35.85M 32.03%	50.23M 40.11%
total current assets	11.44M -	5.92M 48.24%	13.29M 124.55%	52.40M 294.17%	35.04M 33.13%	49.60M 41.56%
total current liabilities	11.78M -	24.59M 108.85%	40.61M 65.12%	33.95M 16.40%	21.05M 38%	10.83M 48.56%
total debt		64.05M -	122.04M 90.53%	16.24M 86.69%	9M 44.59%	13.66M 51.73%
total investments
total liabilities	223.15M -	298.44M 33.74%	402.23M 34.78%	35.48M 91.18%	46.22M 30.29%	95.52M 106.67%
total liabilities and stockholders equity	13.32M -	7.15M 46.29%	15.52M 116.95%	52.74M 239.78%	35.85M 32.03%	50.23M 40.11%
total non current assets	1.88M -	1.23M 34.46%	2.23M 80.53%	345K 84.52%	808K 134.20%	624K 22.77%
total non current liabilities	211.38M -	273.85M 29.55%	361.62M 32.05%	1.53M 99.58%	25.17M 1,549.48%	84.69M 236.47%
total stockholders equity	-209.83M -	-291.29M 38.82%	-386.71M 32.76%	17.27M 104.47%	-10.37M 160.07%	-45.30M 336.70%

COM:STEALTHBT

Stealth BioTherapeutics

Last Close

0.32

15/11 21:00

Volume Today

1.30M

Avg: -

Preview